Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

BACKGROUND: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients. METHODS: Ninety patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludwig, Heinz, Poenisch, Wolfram, Knop, Stefan, Egle, Alexander, Schreder, Martin, Lechner, Daniel, Hajek, Roman, Gunsilius, Eberhard, Krenosz, Karl Jochen, Petzer, Andreas, Weisel, Katja, Niederwieser, Dietger, Einsele, Hermann, Willenbacher, Wolfgang, Melchardt, Thomas, Greil, Richard, Zojer, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889132/
https://www.ncbi.nlm.nih.gov/pubmed/31558804
http://dx.doi.org/10.1038/s41416-019-0581-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889132/
https://www.ncbi.nlm.nih.gov/pubmed/31558804
http://dx.doi.org/10.1038/s41416-019-0581-8

Ejemplares similares